DE69936515D1 - Aerosolformulierungen von salmeterol xinafoate - Google Patents
Aerosolformulierungen von salmeterol xinafoateInfo
- Publication number
- DE69936515D1 DE69936515D1 DE69936515T DE69936515T DE69936515D1 DE 69936515 D1 DE69936515 D1 DE 69936515D1 DE 69936515 T DE69936515 T DE 69936515T DE 69936515 T DE69936515 T DE 69936515T DE 69936515 D1 DE69936515 D1 DE 69936515D1
- Authority
- DE
- Germany
- Prior art keywords
- formulations
- salmeterol xinafoate
- xinafoate
- salmeterol
- aerosol formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9808802.4A GB9808802D0 (en) | 1998-04-24 | 1998-04-24 | Pharmaceutical formulations |
GB9808802 | 1998-04-24 | ||
PCT/EP1999/002748 WO1999055319A1 (en) | 1998-04-24 | 1999-04-23 | Aerosol formulations of salmeterol xinafoate |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69936515D1 true DE69936515D1 (de) | 2007-08-23 |
DE69936515T2 DE69936515T2 (de) | 2007-11-22 |
Family
ID=10830947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69936515T Revoked DE69936515T2 (de) | 1998-04-24 | 1999-04-23 | Aerosolformulierungen von salmeterol xinafoate |
Country Status (9)
Country | Link |
---|---|
US (1) | US6613307B1 (de) |
EP (1) | EP1073429B1 (de) |
JP (1) | JP2002512952A (de) |
AT (1) | ATE366568T1 (de) |
AU (1) | AU3821399A (de) |
DE (1) | DE69936515T2 (de) |
ES (1) | ES2289811T3 (de) |
GB (1) | GB9808802D0 (de) |
WO (1) | WO1999055319A1 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1523976A3 (de) * | 1999-11-23 | 2005-06-22 | Glaxo Group Limited | Pharmazeutische Formulierungen enthaltend Salmeterol |
ES2238334T3 (es) * | 1999-12-24 | 2005-09-01 | Glaxo Group Limited | Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona. |
AR030516A1 (es) * | 2000-08-31 | 2003-08-20 | Glaxo Group Ltd | Uso de una combinacion de salmeterol y fluticasona |
US6596262B2 (en) * | 2001-02-15 | 2003-07-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6475468B2 (en) * | 2001-02-15 | 2002-11-05 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6551578B2 (en) * | 2001-02-15 | 2003-04-22 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6544497B2 (en) * | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
US6485707B2 (en) | 2001-02-15 | 2002-11-26 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
US6915966B2 (en) * | 2003-01-29 | 2005-07-12 | Specialty Minerals (Michigan) Inc. | Apparatus for the gunning of a refractory material and nozzles for same |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
US20080118442A1 (en) * | 2003-09-10 | 2008-05-22 | Map Pharmaceuticals, Inc. | Aerosol Formulations for Delivery of Dihydroergotamine to the Systemic Circulations Via Pulmonary Inhalation |
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
RU2006136025A (ru) * | 2004-03-12 | 2008-04-20 | Сипла Лимитед (In) | Ингаляционные композиции |
US20070203700A1 (en) * | 2004-03-30 | 2007-08-30 | Soichi Toyama | Speech Recognition Apparatus And Speech Recognition Method |
WO2005105765A1 (en) | 2004-05-05 | 2005-11-10 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
US7968575B2 (en) | 2004-05-05 | 2011-06-28 | Renopharm Ltd. | Nitric oxide donors and uses thereof |
US7498445B2 (en) | 2004-05-05 | 2009-03-03 | Renopharm Ltd. | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof |
US8134010B2 (en) | 2004-05-05 | 2012-03-13 | Renopharm Ltd. | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof |
US7569586B2 (en) | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
GB0418791D0 (en) * | 2004-08-23 | 2004-09-22 | Glaxo Group Ltd | Novel process |
US7854397B2 (en) * | 2005-01-21 | 2010-12-21 | Specialty Minerals (Michigan) Inc. | Long throw shotcrete nozzle |
PL2425820T3 (pl) | 2007-02-11 | 2015-08-31 | Map Pharmaceuticals Inc | Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych |
US20090048155A1 (en) | 2007-08-15 | 2009-02-19 | Endacea, Inc. | Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection |
KR101225233B1 (ko) * | 2007-09-05 | 2013-01-22 | 화이자 리미티드 | N4-(2,2-다이플루오로-4h-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-n2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염 |
WO2010091198A1 (en) | 2009-02-06 | 2010-08-12 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
DK2453894T3 (en) | 2009-07-15 | 2016-01-25 | Theravance Biopharma R&D Ip Llc | Crystalline free base of a biphenyl compound |
WO2011094208A2 (en) | 2010-01-26 | 2011-08-04 | Endacea, Inc. | Methods and pharmaceutical compositions for preventing and treating renal impairment |
EP2542082B8 (de) | 2010-03-03 | 2020-06-17 | Neonc Technologies Inc. | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT (S)-Perillylalkohol |
EP2571486A4 (de) * | 2010-05-20 | 2013-12-04 | Sun Pharma Advanced Res Co Ltd | Trockenpulverinhalationszusammensetzung |
US20160038600A1 (en) | 2012-08-03 | 2016-02-11 | Neonc Technologies Inc. | Pharmaceutical compositions comprising poh derivatives |
CN110464718A (zh) | 2010-08-27 | 2019-11-19 | 尼昂克技术公司 | 包含poh衍生物的药物组合物 |
WO2012032546A2 (en) | 2010-09-08 | 2012-03-15 | Cadila Healthcare Limited | Process for the preparation of salmeterol and its intermediates |
DK2651864T3 (en) | 2010-12-17 | 2016-09-05 | Neonc Tech Inc | Methods and devices for use of isoperillylalkohol |
CA2902403C (en) | 2013-03-15 | 2021-06-01 | Verona Pharma Plc | Pde3/pde4 inhibitor/muscarinic receptor antagonist combination |
PT3231444T (pt) | 2014-05-12 | 2020-03-05 | Verona Pharma Plc | Novo tratamento |
WO2015199626A1 (en) * | 2014-06-27 | 2015-12-30 | World Medicine İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | STABLE AEROSOL FORMULATIONS OF β2- ADRENERGIC AGONISTS |
KR20170131405A (ko) | 2015-02-12 | 2017-11-29 | 네온씨 테크놀로지스, 아이엔씨. | 페릴릴 알코올 유도체를 포함하는 의약 조성물 |
JP7144411B2 (ja) | 2016-11-30 | 2022-09-29 | ネオンク テクノロジーズ インク. | ペリリルアルコール-3-ブロモピルベート複合体及びがんの治療方法 |
US20210228498A1 (en) | 2018-02-08 | 2021-07-29 | Neonc Technologies, Inc. | Methods of permeabilizing the blood brain barrier |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3706598A (en) * | 1970-07-15 | 1972-12-19 | Cpc International Inc | Solid,glass-like starch hydrolysates having high densities |
JPH05500229A (ja) * | 1991-04-12 | 1993-01-21 | 東レ株式会社 | 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法 |
ATE128350T1 (de) * | 1991-12-12 | 1995-10-15 | Glaxo Group Ltd | Pharmazeutische aerosolformulierung. |
US5683676A (en) * | 1991-12-12 | 1997-11-04 | Glaxo Group Limited | Canister containing aerosol formulations containing P134a and particulate medicaments |
US5301664A (en) * | 1992-03-06 | 1994-04-12 | Sievers Robert E | Methods and apparatus for drug delivery using supercritical solutions |
GB9313650D0 (en) * | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
ATE387925T1 (de) * | 1994-09-21 | 2008-03-15 | Nektar Therapeutics | Vorrichtung und verfahren zum dispergieren von trockenen pulvermedikamenten |
JP2860951B2 (ja) * | 1995-01-12 | 1999-02-24 | 株式会社萩原技研 | 抗菌性ポリマー組成物 |
US5780014A (en) * | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
AP979A (en) * | 1995-04-14 | 2001-06-28 | Glaxo Wellcome Inc | Metered dose imhaler for salmeterol. |
US5977010A (en) * | 1995-06-15 | 1999-11-02 | Engelhard Corporation | Shaped hydrogenation catalyst and processes for their preparation and use |
GB9606677D0 (en) * | 1996-03-29 | 1996-06-05 | Glaxo Wellcome Inc | Process and device |
-
1998
- 1998-04-24 GB GBGB9808802.4A patent/GB9808802D0/en not_active Ceased
-
1999
- 1999-04-23 EP EP99920757A patent/EP1073429B1/de not_active Revoked
- 1999-04-23 AT AT99920757T patent/ATE366568T1/de not_active IP Right Cessation
- 1999-04-23 DE DE69936515T patent/DE69936515T2/de not_active Revoked
- 1999-04-23 US US09/646,872 patent/US6613307B1/en not_active Expired - Fee Related
- 1999-04-23 ES ES99920757T patent/ES2289811T3/es not_active Expired - Lifetime
- 1999-04-23 WO PCT/EP1999/002748 patent/WO1999055319A1/en active IP Right Grant
- 1999-04-23 AU AU38213/99A patent/AU3821399A/en not_active Abandoned
- 1999-04-23 JP JP2000545518A patent/JP2002512952A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1073429A1 (de) | 2001-02-07 |
EP1073429B1 (de) | 2007-07-11 |
ES2289811T3 (es) | 2008-02-01 |
ATE366568T1 (de) | 2007-08-15 |
WO1999055319A1 (en) | 1999-11-04 |
AU3821399A (en) | 1999-11-16 |
DE69936515T2 (de) | 2007-11-22 |
GB9808802D0 (en) | 1998-06-24 |
US6613307B1 (en) | 2003-09-02 |
JP2002512952A (ja) | 2002-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE366568T1 (de) | Aerosolformulierungen von salmeterol xinafoate | |
FI956343A0 (fi) | Säädellyn hiukkaskoon omaava salmeteroliksinafoaatti | |
TR200100144T2 (tr) | Farmasötik aerosol formülasyonu | |
ZA200301813B (en) | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them. | |
HUP0301688A3 (en) | Amino alcohol derivatives, process for their preparation and pharmaceutical compositions containing them | |
DK0717617T3 (da) | Mikropartikler indeholdende aktive bestanddele og gas | |
HUP0101281A3 (en) | Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them | |
HUP0303722A3 (en) | Urea derivatives as integrin alpha 4 antanists, process for their preparation and pharmaceutical compositions containing them | |
HUP0300894A3 (en) | Substituted beta-carbolines, process for their preparation, pharmaceutical compositions containing them and their use | |
AR020392A1 (es) | Formulaciones microencapsuladas. | |
HUP0401201A3 (en) | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments | |
HUP0301075A3 (en) | Diphenyl ether derivatives, their use for preparation of pharmaceutical compositions and process for preparation the compounds | |
AR020391A1 (es) | Formulaciones microencapsuladas, un procedimiento para su obtencion y empleo de dichas formulaciones. | |
HUP0204202A3 (en) | Ibuprofen containing active agent preparation, process for its preparation and pharmaceutical compositions containing it | |
MXPA03009984A (es) | PREPARACION PARA LA REMOCIoN DE MATERIAL QUERATINOSO ANORMAL. | |
HUP0401369A3 (en) | Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof | |
WO2002034240A3 (en) | Delayed and sustained release formulations and method of use thereof | |
HUP0303195A3 (en) | O-substituted 6-methyl-tramadol derivatives, process for their preparation and pharmaceutical compositions containing them | |
WO2002000191A3 (de) | Bdellosomen | |
HUP0303804A3 (en) | Ligands of the avss6 integrin, process for their preparation, their use and pharmaceutical compositions containing them | |
EP1245562A4 (de) | 5-thia-"omega"-(substituiertes phenyl)-prostaglandin e alkohole, verfahren zur herstellung der alkohole und pharmzeutische zusammensetzungen, die diese als aktive inhaltsstoffe enthalten | |
ZA200300777B (en) | Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts. | |
MXPA00012442A (es) | Dextrosa hidratada pulcverizada y su procedimiento de preparacion. | |
ES2145162T3 (es) | Procedimiento para preparar aminas aromaticas sustituidas. | |
NO20042022L (no) | Fast legemiddelformulering som inneholder pipiperazinurea-derivat og fremgangsmate for fremstilling av formuleringen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8331 | Complete revocation |